Medication consent
Informed Consent for Treatment with Prolia (denosumab)
Informed consent for treatment with Prolia.
About this form
Prolia (denosumab) is used to treat osteoporosis in postmenopausal women and men at high risk of fracture, glucocorticoid-induced osteoporosis, and bone loss in patients on certain cancer therapies. It works by binding RANKL to inhibit bone resorption.
- !Hypocalcemia can occur — calcium and vitamin D supplementation is required.
- !Stopping treatment without follow-up therapy can lead to rapid bone loss and an increased risk of vertebral fractures. Do not delay or skip doses.
- !Serious skin infections, osteonecrosis of the jaw, and atypical femur fractures have been reported.
- !Patients should report dental pain or new thigh / groin pain promptly.
Trouble with the form?
Call our office and we'll either walk you through it or send a paper version.